Common Myths in Psychedelic Law

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Anyone who has read something about psychedelic legality — in the news, on a company’s website, from a friend, or in an advocacy publication — and wants to know whether it’s accurate. These are the mistakes we see most often, and they matter because people make real decisions based on them.

”Psilocybin is legal in Oregon, so I can buy it anywhere there.”

Oregon’s program authorizes the supervised use of psilocybin at licensed service centers by licensed facilitators. Adults 21 and older can access these services, but only at a licensed center, only during a session supervised by a licensed facilitator, and only with psilocybin produced by a licensed manufacturer within the Oregon system. You cannot purchase psilocybin at a dispensary, take it home, or buy it from an unlicensed seller. Oregon has a regulated program. It does not have a retail market.

”Colorado decriminalized all psychedelics, so anything goes there.”

Colorado’s Proposition 122 did two distinct things that are frequently conflated. First, it decriminalized personal use, possession, and cultivation of psilocybin, psilocin, DMT, ibogaine, and mescaline (excluding peyote) for adults 21 and older. Second, it created a licensed healing center framework for supervised psilocybin services. The decriminalization covers personal use in private — it does not authorize sale, distribution, or commercial facilitation. Selling any of these substances remains a crime under Colorado and federal law. The licensed program currently covers psilocybin and psilocin only. DMT, ibogaine, and mescaline are not yet available through licensed healing centers.

”The FDA said psilocybin is a breakthrough therapy, so it’s approved.”

Breakthrough Therapy designation is a research and development status that allows the FDA to work more closely with a drug sponsor to accelerate clinical development. The designation carries no approval authority and does not authorize any use, prescription, or administration of the substance. COMPASS Pathways received Breakthrough Therapy designation for psilocybin in treatment-resistant depression in 2018. Usona Institute received one for major depressive disorder in 2019. Neither designation has resulted in FDA approval, and no psychedelic other than esketamine (Spravato) has received full FDA approval for any indication. Breakthrough Therapy designation does not change a substance’s Schedule I status.

”MDMA-assisted therapy was rejected because the FDA thinks it doesn’t work.”

The FDA’s August 2024 Complete Response Letter to Lykos Therapeutics declined to approve MDMA-assisted therapy for PTSD — but the rejection was not a finding that MDMA is ineffective. The FDA’s stated concerns were about trial design, functional unblinding (participants could tell whether they received active drug or placebo), data integrity issues at two research sites, the durability of the treatment effect beyond the 18-week assessment window, and the high rate of prior MDMA use among participants creating potential selection bias. The FDA asked for an additional Phase 3 trial to address these concerns. It did not conclude that MDMA therapy fails to work.

”If I participate in an Oregon or Colorado session, I’m protected from federal prosecution.”

Oregon and Colorado state law authorizes activities within their licensed frameworks. Federal law does not recognize these authorizations. The Controlled Substances Act classifies psilocybin as Schedule I regardless of what Oregon or Colorado has enacted. No participant in a state-licensed session has federal legal immunity. In practice, the federal government has not prosecuted participants in the Oregon program, and prosecutorial priorities at the federal level have shifted away from low-level psychedelic possession. But “shifted priorities” is not the same as “legal protection,” and federal jurisdiction has not been waived.

”My city decriminalized it, so I’m fine.”

City decriminalization directs local police to deprioritize enforcement of personal possession. It does not change state law. It does not bind state law enforcement agencies. It does not bind federal authorities. A person arrested by state police or federal agents in a decriminalized city has no protection from that city’s measure. The federal prosecution of Kole Milner in Denver — after Denver decriminalized psilocybin — illustrates the point directly: the US Attorney’s office proceeded with charges and Milner pleaded guilty. City decriminalization reduces local arrest risk. It does not eliminate legal risk from other levels of government.

”Because it’s a plant, it’s legal.”

The federal Controlled Substances Act schedules specific chemical compounds, not just processed drugs. Psilocybin and psilocin are scheduled compounds regardless of the form they appear in — including whole mushrooms. DMT is a scheduled compound regardless of whether it appears in a plant, a brew, or a synthesized form. Mescaline is scheduled regardless of whether it comes from a peyote cactus, a San Pedro cactus, or a laboratory. The “natural” origin of a substance does not change its federal legal status.

”Ayahuasca is legal in Peru, so Americans can do ceremonies there without worrying about US law.”

A US citizen’s activities in Peru during a ceremony are generally not subject to the CSA for what happens abroad, provided there is no intent to import controlled substances into the United States. The concern comes at the border. Bringing ayahuasca — which contains DMT, a Schedule I substance — into the United States is a federal importation crime under 21 U.S.C. § 952, regardless of where the substance was legally acquired. The fact that the ceremony was legal where it happened provides no defense to importation charges when re-entering the US.

”Calling ourselves a church protects our psychedelic ceremony legally.”

The Religious Freedom Restoration Act (RFRA) provides a mechanism for religious organizations to seek exemptions from the Controlled Substances Act for the sacramental use of controlled substances. That mechanism requires either a court judgment in the organization’s favor or a formal DEA exemption obtained through the petition process. Neither happens automatically from adopting a religious organizational form. A church incorporation, a website, a membership card, or a sincere claim of religious belief does not create RFRA protection. As of early 2026, RFRA exemptions for psychedelic use cover ayahuasca only, for specific recognized organizations. No exemption covers psilocybin.

”Ketamine therapy is the same category of thing as psilocybin therapy legally.”

Ketamine and psilocybin occupy entirely different legal positions. Ketamine is a Schedule III controlled substance with FDA approval as an anesthetic and widespread off-label prescribing for depression and PTSD. Esketamine (Spravato) is FDA-approved for treatment-resistant depression. Licensed physicians can prescribe ketamine today. Ketamine clinics operate legally under federal law. Psilocybin is Schedule I with no FDA-approved indication, no prescription pathway, and access only through Oregon, Colorado, and New Mexico’s state programs or authorized clinical trials. Grouping them together as “psychedelic therapy” describes their clinical framing — not their legal status.

”Decriminalization means it’s legal to sell.”

Every city and county decriminalization measure reviewed in this library covers personal possession and personal use only. Commercial sale of psilocybin or any other decriminalized psychedelic is explicitly excluded from coverage in every measure. Selling psilocybin — anywhere in the United States, including in the most permissive decriminalized jurisdictions — remains a criminal offense under state and federal law. Even within Oregon and Colorado’s licensed programs, sale outside the licensed system is illegal.

”Research shows it works, so the government has to make it available.”

Federal drug law does not respond automatically to efficacy research. Clinical evidence of a drug’s therapeutic value does not change its legal classification. That change requires either an act of Congress, a completed DEA rulemaking (which itself requires an HHS scientific evaluation and full notice-and-comment procedure), or FDA approval of a drug product followed by DEA scheduling of that product. Promising Phase 2 and Phase 3 trial data for psilocybin and MDMA existed for years before MDMA was rejected and before any psilocybin product has reached an NDA submission. The research track and the legal track operate on different timelines under different mechanisms.

”If I attend a wellness retreat, I’m not really breaking any laws.”

Whether a retreat is operating legally depends on its structure, jurisdiction, what substances are involved, and what the facilitators are doing. Many retreat operations — both within the United States and abroad — handle Schedule I controlled substances without any federal authorization. In states without licensed programs, a wellness retreat serving psilocybin is facilitating possession and distribution of a Schedule I substance. In decriminalized cities, commercial facilitation is not covered by the decriminalization measure. Retreat operators and participants in unlicensed settings have no legal protection at the federal level, and usually none at the state level. The existence of a website, a waiver, and a “facilitator” does not create legal authorization.

”My therapist referred me, so my session is medically authorized.”

A therapist or counselor who refers a client to a psychedelic retreat or session — in the United States or abroad — is making a personal recommendation, not a medical authorization under federal law. No licensed therapist has the authority to authorize the administration of a Schedule I controlled substance outside an FDA-authorized clinical trial. The referral does not change the legal status of what happens in the session, does not protect the therapist from licensing board scrutiny, and does not protect the client from the legal consequences of participating in an unauthorized session.

”If rescheduling happens, psilocybin becomes legal everywhere.”

Rescheduling would change psilocybin’s classification within the Controlled Substances Act from Schedule I to a lower schedule. This would remove the bar on prescribing for an FDA-approved drug product and reduce some research restrictions. It would not federally legalize general possession, sale, or manufacture. Non-prescription use would remain controlled. State laws would still need to accommodate the new federal status — in some states automatically, in others through separate legislative or regulatory action. Rescheduling would create a prescribable pathway for an FDA-approved psilocybin drug product if one existed, not a general authorization for psilocybin in any form or context.

”Because this is changing so fast, the current law probably doesn’t matter much.”

The fact that law in this area is changing does not make the current law inapplicable. A federal prosecution for psilocybin distribution under the Controlled Substances Act applies the law as it exists today, not the law as it might exist after future reform. A licensing board investigation of a healthcare professional who participated in an unauthorized psychedelic session proceeds under current law. An employer drug test that returns a positive result for a controlled substance has consequences under current employment law. The trajectory of reform matters for long-term planning. Current law matters for decisions made today.

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.